InfuSystem Holdings (INFU) Net Income towards Common Stockholders (2010 - 2026)
InfuSystem Holdings (INFU) posted Net Income towards Common Stockholders of $1.0 million for Q1 2026, down 50.68% on a QoQ basis from $2.1 million in Q4 2025, and up 562.27% year-over-year from $153562.1 in Q1 2025.
InfuSystem Holdings (INFU) Net Income towards Common Stockholders (2010 - 2026) Analysis & Trends
InfuSystem Holdings' Net Income towards Common Stockholders history runs 17 years deep, the most recent figure standing at $1.0 million for Q1 2026.
- Quarterly Net Income towards Common Stockholders rose 562.27% year-over-year to $1.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.9 million (up 147.29% YoY) and the FY2025 annual result came in at $6.6 million, up 182.6% from the prior year.
- Net Income towards Common Stockholders was $1.0 million for Q1 2026 at InfuSystem Holdings, down from $2.1 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at $2.6 million in Q2 2025 and bottomed at -$1.1 million in Q1 2024.
- A 5-year average of $652235.3 and a median of $443000.0 in 2022 frame the typical range for Net Income towards Common Stockholders.
- Peak annual rise in Net Income towards Common Stockholders reached 884.38% in 2024, while the deepest fall reached 266.0% in 2024.
- InfuSystem Holdings' Net Income towards Common Stockholders stood at $138000.0 in 2022, then sank by 30.43% to $96000.0 in 2023, then soared by 884.38% to $945000.0 in 2024, then jumped by 118.2% to $2.1 million in 2025, then tumbled by 50.68% to $1.0 million in 2026.
- Business Quant data shows INFU's Net Income towards Common Stockholders at $1.0 million in Q1 2026, $2.1 million in Q4 2025, and $2.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.32 Bn | 175.02 Bn | 6.27 Bn | 1.08 Bn |
| 2 | Stryker | 128.75 Bn | 125.88 Bn | 3.81 Bn | 745.00 Mn |
| 3 | Medtronic | 107.83 Bn | 98.61 Bn | 6.41 Bn | 1.26 Bn |
| 4 | Boston Scientific | 67.61 Bn | 66.15 Bn | 3.61 Bn | 1.34 Bn |
| 5 | Edwards Lifesciences | 48.13 Bn | 44.45 Bn | 1.29 Bn | - |
| 6 | Dexcom | 28.26 Bn | 27.14 Bn | 750.30 Mn | 199.50 Mn |
| 7 | GE HealthCare Technologies | 27.78 Bn | 25.50 Bn | 1.98 Bn | 411.00 Mn |
| 8 | Smith & Nephew | 26.99 Bn | 26.41 Bn | - | - |
| 9 | Koninklijke Philips | 23.92 Bn | 20.80 Bn | 2.07 Bn | 176.78 Mn |
| 10 | InfuSystem Holdings | 188.97 Mn | 186.87 Mn | 19.68 Mn | 1.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.02 Mn |
| Dec 31, 2025 | 2.06 Mn |
| Sep 30, 2025 | 2.26 Mn |
| Jun 30, 2025 | 2.60 Mn |
| Mar 31, 2025 | -220,000.00 |
| Dec 31, 2024 | 945,000.00 |
| Sep 30, 2024 | 1.79 Mn |
| Jun 30, 2024 | 700,000.00 |
| Mar 31, 2024 | -1.10 Mn |
| Dec 31, 2023 | 96,000.00 |
| Sep 30, 2023 | 720,000.00 |
| Jun 30, 2023 | 435,000.00 |
| Mar 31, 2023 | -300,000.00 |
| Dec 31, 2022 | 138,000.00 |
| Sep 30, 2022 | 443,000.00 |
| Jun 30, 2022 | -164,000.00 |
| Mar 31, 2022 | -330,000.00 |
| Dec 31, 2021 | 387,000.00 |
| Sep 30, 2021 | -448,000.00 |
| Jun 30, 2021 | 842,000.00 |